BACKGROUND: Geldanamycin (GA) can be considered a relatively new component with a promising mode of action against human malignancies.
It specifically targets heat shock protein 90 (Hsp90) and interferes with its function as a molecular chaperone.
METHODS: In this study, we have investigated the effects of geldanamycin on the regulation of Hsp90-dependent oncogenic signaling pathways directly implicated in cell cycle progression, survival and motility of human urinary bladder cancer cells. In order to assess the biological outcome of Hsp90 inhibition on RT4 (grade I) and T24 (grade III) human urinary bladder cancer cell lines, we applied MTT assay, FACS analysis, Western blotting, semi-quantitative (sq) RT-PCR, electrophoretic mobility shift assay (EMSA), immunofluorescence and scratch-wound assay.
RESULTS: We have herein demonstrated that, upon geldanamycin treatment, bladder cancer cells are prominently arrested in the G1 phase of cell cycle and eventually undergo programmed cell death via combined activation of apoptosis and autophagy. Furthermore, geldanamycin administration proved to induce prominent downregulation of several Hsp90 protein clients and downstream effectors, such as membrane receptors (IGF-IR and c-Met), protein kinases (Akt, IKKα, IKKβ and Erk1/2) and transcription factors (FOXOs and NF-κΒ), therefore resulting in the impairment of proliferative -oncogenic- signaling and reduction of cell motility.
CONCLUSIONS: In toto, we have evinced the dose-dependent and cell line-specific actions of geldanamycin on cell cycle progression, survival and motility of human bladder cancer cells, due to downregulation of critical Hsp90 clients and subsequent disruption of signaling -oncogenic- integrity.
Written by:
Karkoulis PK, Stravopodis DJ, Konstantakou EG, Voutsinas GE. Are you the author?
Laboratory of Environmental Mutagenesis and Carcinogenesis, Institute of Biosciences and Applications, National Center for Scientific Research (NCSR) "Demokritos", Aghia Paraskevi, 15310, Athens, Greece.
Reference: Cancer Cell Int. 2013 Feb 8;13(1):11.
doi: 10.1186/1475-2867-13-11
PubMed Abstract
PMID: 23394616
UroToday.com Investigative Urology Section
